Cervomed Inc.
06/18/2026 | Press release | Distributed by Public on 06/18/2026 05:22
Material Event (Form 8-K)
Item 8.01 Other Events
On June 16, 2026, CervoMed Inc. (the "Company") received a notice of allowance from the United States Patent and Trademark Office related to a new patent protecting the Company's use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies in patients with no substantial Alzheimer's disease-like tau pathology, which is expected to provide intellectual property protection into 2042 (without giving effect to any potential patent term extension).
Cervomed Inc. published this content on June 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 18, 2026 at 11:22 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]